Zoetis/$ZTS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Ticker

$ZTS
Sector

Primary listing

NYSE

Employees

13,800

Zoetis Metrics

BasicAdvanced
$66B
25.69
$5.82
0.89
$1.93
1.34%

What the Analysts think about Zoetis

Analyst ratings (Buy, Hold, Sell) for Zoetis stock.

Bulls say / Bears say

Zoetis delivered 8% organic operational revenue growth and 10% organic operational adjusted net income growth in Q2 2025, with reported net income up 15%, and raised its full-year revenue guidance to $9.45–$9.60 billion and adjusted EPS guidance to $6.30–$6.40, showing strong first-half performance (Reuters).
The companion animal segment posted 8% organic operational revenue growth to $1.79 billion in Q2 2025, lifted by strong demand for Simparica Trio and top dermatology products like Apoquel and Cytopoint (Reuters).
Zoetis reduced its 2025 adjusted cost of sales guidance to about 28.0% of revenue, down from 28.5%, indicating greater margin expansion potential from improved operational efficiency (Business Wire).
US livestock sales dropped 21% year-over-year and declined 2% on an organic operational basis in Q2 2025, mainly due to the sale of the medicated feed additive portfolio and supply timing issues, highlighting ongoing challenges in the production animal division (Business Wire).
Zoetis is facing stronger competition from Merck’s Numelvi and Elanco’s Zenrelia and CQ in important dermatology and parasiticide markets, with Stifel survey data pointing to increased veterinarian adoption of these competing therapies (Barron's).
Stifel Nicolaus downgraded Zoetis from Buy to Hold and reduced its price target, citing worries over slowing revenue growth through 2027 and stalled international expansion, indicating risks to the company’s near-term growth prospects (Barron's).
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

Zoetis Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Zoetis Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZTS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs